Radiopharm Theranostics (ASX:RAD) to Attend Key Global Healthcare Conferences

March 13, 2025 11:40 AM AEDT | By Sonal Goyal

Radiopharm Theranostics (ASX:RAD) to Attend Key Global Healthcare Conferences — Image source: Company update

Recent News

EcoGraf (ASX: EGR) Advances in Graphite Production with Successful PQF...

Legacy focuses on commodity price trends while releasing the Drake MRE...

After a global search, Nine has promoted Matt Stanton from acting CEO...

Mining Sector Developments Influence Market Movements on the ASX

Highlights

Radiopharm Theranostics is participating in multiple upcoming healthcare conferences.

Voliotis, RAD’s Chief Medical Officer, is attending the Leerink Partners event in Miami, Florida.

Voliotis is scheduled to present at the NWR Virtual Healthcare Conference on 19 March 2025.

Radiopharm Theranostics (ASX:RAD), a developer of advanced radiopharmaceutical products for both diagnostic and therapeutic applications, has announced its participation in several upcoming and ongoing healthcare conferences.

RAD’s Chief Medical Officer, Dr. Dimitris Voliotis, is attending the Leerink Partners Global Healthcare Conference 2025, taking place this week in Miami, Florida, USA. Dr. Voliotis will participate in numerous meetings with professional and institutional investors

Additionally, Dr. Voliotis is scheduled to present at the NWR Virtual Healthcare Conference on Wednesday, 19 March 2025

RAD shares were trading over 7% higher at AU$0.029 per share at the time of writing on 13 March 2025.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. With a deep pipeline of differentiated molecules—peptides, small molecules, and monoclonal antibodies—the company focuses on cancer treatment in pre-clinical and clinical stages. The pipeline aims to be first-to-market or best-in-class, with one Phase II and three Phase I trials targeting solid tumours, including brain, lung, breast, and pancreatic cancers.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.